These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25267004)

  • 41. From orexin receptor agonist YNT-185 to novel antagonists with drug-like properties for the treatment of insomnia.
    Mezeiova E; Janockova J; Konecny J; Kobrlova T; Benkova M; Dolezal R; Prchal L; Karasova-Zdarova J; Soukup O; Korabecny J
    Bioorg Chem; 2020 Oct; 103():104179. PubMed ID: 32891860
    [TBL] [Abstract][Full Text] [Related]  

  • 42. (+/-)-(Z)-2-(aminomethyl)-1-phenylcyclopropanecarboxamide derivatives as a new prototype of NMDA receptor antagonists.
    Shuto S; Takada H; Mochizuki D; Tsujita R; Hase Y; Ono S; Shibuya N; Matsuda A
    J Med Chem; 1995 Jul; 38(15):2964-8. PubMed ID: 7636857
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist.
    Beuckmann CT; Suzuki M; Ueno T; Nagaoka K; Arai T; Higashiyama H
    J Pharmacol Exp Ther; 2017 Aug; 362(2):287-295. PubMed ID: 28559480
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist.
    Steiner MA; Gatfield J; Brisbare-Roch C; Dietrich H; Treiber A; Jenck F; Boss C
    ChemMedChem; 2013 Jun; 8(6):898-903. PubMed ID: 23589487
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of a new series of non-peptidic NK3 receptor antagonists.
    Juhl K; Hansen T; Kehler J; Khanzhin NA; Nørgaard MB; Ruhland T; Larsen DB; Jensen KG; Steiniger-Brach B; Nielsen SM; Simonsen KB
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1498-501. PubMed ID: 21292483
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors.
    Yin J; Babaoglu K; Brautigam CA; Clark L; Shao Z; Scheuermann TH; Harrell CM; Gotter AL; Roecker AJ; Winrow CJ; Renger JJ; Coleman PJ; Rosenbaum DM
    Nat Struct Mol Biol; 2016 Apr; 23(4):293-9. PubMed ID: 26950369
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Azulene-based compounds for targeting orexin receptors.
    Leino TO; Turku A; Yli-Kauhaluoma J; Kukkonen JP; Xhaard H; Wallén EAA
    Eur J Med Chem; 2018 Sep; 157():88-100. PubMed ID: 30077889
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Suvorexant: a novel therapy for the treatment of insomnia.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2014 Oct; 52(10):23-6. PubMed ID: 25291725
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Orexin receptor antagonists: a review of promising compounds patented since 2006.
    Coleman PJ; Renger JJ
    Expert Opin Ther Pat; 2010 Mar; 20(3):307-24. PubMed ID: 20180618
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders.
    Di Fabio R; Pellacani A; Faedo S; Roth A; Piccoli L; Gerrard P; Porter RA; Johnson CN; Thewlis K; Donati D; Stasi L; Spada S; Stemp G; Nash D; Branch C; Kindon L; Massagrande M; Poffe A; Braggio S; Chiarparin E; Marchioro C; Ratti E; Corsi M
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5562-7. PubMed ID: 21831639
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Almorexant, a dual orexin receptor antagonist for the treatment of insomnia.
    Neubauer DN
    Curr Opin Investig Drugs; 2010 Jan; 11(1):101-10. PubMed ID: 20047164
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacology for insomnia: consider the options.
    Rosini JM; Dogra P
    Nursing; 2015 Mar; 45(3):38-45; quiz 45-6. PubMed ID: 25646892
    [No Abstract]   [Full Text] [Related]  

  • 53. Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.
    Stasi LP; Artusi R; Bovino C; Buzzi B; Canciani L; Caselli G; Colace F; Garofalo P; Giambuzzi S; Larger P; Letari O; Mandelli S; Perugini L; Pucci S; Salvi M; Toro P
    Bioorg Med Chem Lett; 2013 May; 23(9):2653-8. PubMed ID: 23535328
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The action of orexin B on passive avoidance learning. Involvement of neurotransmitters.
    Palotai M; Telegdy G; Ekwerike A; Jászberényi M
    Behav Brain Res; 2014 Oct; 272():1-7. PubMed ID: 24931796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure-Based Discovery of Novel Ligands for the Orexin 2 Receptor.
    Gunera J; Baker JG; van Hilten N; Rosenbaum DM; Kolb P
    J Med Chem; 2020 Oct; 63(19):11045-11053. PubMed ID: 32977721
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and SAR of 2-phenyl-1-sulfonylaminocyclopropane carboxylates as ADAMTS-5 (Aggrecanase-2) inhibitors.
    Shiozaki M; Imai H; Maeda K; Miura T; Yasue K; Suma A; Yokota M; Ogoshi Y; Haas J; Fryer AM; Laird ER; Littmann NM; Andrews SW; Josey JA; Mimura T; Shinozaki Y; Yoshiuchi H; Inaba T
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6213-7. PubMed ID: 19767207
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypothalamic prepro-orexin mRNA level is inversely correlated to the non-rapid eye movement sleep level in high-fat diet-induced obese mice.
    Tanno S; Terao A; Okamatsu-Ogura Y; Kimura K
    Obes Res Clin Pract; 2013; 7(4):e251-7. PubMed ID: 24306152
    [TBL] [Abstract][Full Text] [Related]  

  • 58. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology.
    Gotter AL; Webber AL; Coleman PJ; Renger JJ; Winrow CJ
    Pharmacol Rev; 2012 Jul; 64(3):389-420. PubMed ID: 22759794
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Eating, sleeping and rewarding: orexin receptors and their antagonists.
    Bingham MJ; Cai J; Deehan MR
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):551-9. PubMed ID: 17002215
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Orexin, Sleep, Sympathetic Neural Activity, and Cardiovascular Function.
    Bigalke JA; Shan Z; Carter JR
    Hypertension; 2022 Dec; 79(12):2643-2655. PubMed ID: 36148653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.